Hyde opens European office

By Nick Taylor

- Last updated on GMT

Related tags: Economics

Hyde Engineering + Consulting has opened an office in Dublin, Ireland, enhancing its ability to provide Europe-based biopharm with compliance, qualification and automation services.

The office is Hyde’s first in Europe, complementing existing sites in the US, India, China, Malaysia and Singapore. Establishing a presence in Europe is intended to improve Hyde’s ability to provide local expertise to existing clients, such as Pfizer and Lonza, and gain new business.

With our European expansion we can now work more closely with facility manufacturers, providing new paradigms for engineering design and operations for compliance​”, explained Simon Forder, CEO of Hyde.

Speaking to in-PharmaTechnologist Will Czerniak, director, European operations at Hyde, added that the company has done business in the region since 1994 and now felt like the right time to expand.

Hyde has experienced an increase in projects in Europe, said Czerniak, and is optimistic that operations will grow in coming years. This is expected to lead to growth and expansion of the company’s services and staff.

Ireland was selected as the office location because of the talent and manufacturing capacity it provides for Hyde’s clients.

Savings in the downturn

Czerniak added that there has been “a dearth of large projects​” during the economic downturn but smaller, more niche work has ensured “Hydeis busier than ever​” and was well ahead of its targets in recent financials.

Forder explained that the economic situation facing biopharm companies means they increasingly “require greater efficiencies and significant reduction in the cost of goods​”.

Hyde believes its services can help achieve these savings. The company’s offering spans process design and engineering, planning and project management, clean-in-place (CIP) and sterilisation-in-place (SIP), compliance engineering and training programmes.

Czerniak added that Hyde has experienced an upturn in projects and spending, giving the company reason to be optimistic that business is growing again.

Related news

Related products

show more

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Related suppliers

Follow us


View more